Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA …
…, L Christelle, MA MOURET-REYNIER… - The Lancet …, 2022 - thelancet.com
Background In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired
resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which …
resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which …
[HTML][HTML] Event-free survival with pembrolizumab in early triple-negative breast cancer
…, M Ferreira, MA Mouret-Reynier… - … England Journal of …, 2022 - Mass Medical Soc
Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …
significantly higher percentage of patients with early triple-negative breast cancer having a …
[HTML][HTML] Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor …
…, AJ Montero, F Forget, MA Mouret-Reynier… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis. …
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis. …
Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
…, E Planchat, C Abrial, MA Mouret-Reynier… - Cancer biology & …, 2010 - Taylor & Francis
Background. Since the improvement of chemotherapy with safe molecules is needed for
better efficacy without supplementary toxicity, we investigated the feasibility and tolerability of …
better efficacy without supplementary toxicity, we investigated the feasibility and tolerability of …
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR …
…, W Janni, R O'Regan, MA Mouret-Reynier… - The Lancet …, 2018 - thelancet.com
Background Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell growth …
that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell growth …
Incorporation of pazopanib in maintenance therapy of ovarian cancer
…, KH Baumann, MA Mouret-Reynier… - Journal of clinical …, 2014 - ascopubs.org
Purpose Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor
receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. …
receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. …
[HTML][HTML] Mutational profile of metastatic breast cancers: a retrospective analysis
…, G Romieu, L Vanlemmens, MA Mouret Reynier… - PLoS …, 2016 - journals.plos.org
Background Major advances have been achieved in the characterization of early breast cancer
(eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes…
(eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes…
Genomics to select treatment for patients with metastatic breast cancer
…, F Coussy, JM Ferrero, G Emile, MA Mouret-Reynier… - Nature, 2022 - nature.com
Cancer progression is driven in part by genomic alterations 1 . The genomic characterization
of cancers has shown interpatient heterogeneity regarding driver alterations 2 , leading to …
of cancers has shown interpatient heterogeneity regarding driver alterations 2 , leading to …
[HTML][HTML] Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
…, M Debled, W Jacot, MA Mouret-Reynier… - European journal of …, 2018 - Elsevier
Aim Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC)
patients may help define medical needs and evaluate the impact of public health …
patients may help define medical needs and evaluate the impact of public health …
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to …
B Coudert, JY Pierga, MA Mouret-Reynier… - The Lancet …, 2014 - thelancet.com
Background An effective and well tolerated treatment is needed for patients with early HER2-positive
breast cancer who do not achieve a pathological complete response after …
breast cancer who do not achieve a pathological complete response after …